$DMAC
DiaMedica Therapeutics Inc.

2019 Q1 Form 10-K Financial Statement

#000143774919005272 Filed on March 19, 2019

View on sec.gov

Income Statement

Concept 2019 Q1 2018 Q4 2017 Q4
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $810.0K $380.0K $760.0K
YoY Change 55.77% -50.0% 300.0%
% of Gross Profit
Research & Development $2.607M $1.740M $650.0K
YoY Change 229.58% 167.69% 54.76%
% of Gross Profit
Depreciation & Amortization $6.000K $10.00K $0.00
YoY Change 50.0%
% of Gross Profit
Operating Expenses $3.421M $2.120M $1.410M
YoY Change 161.94% 50.35% 131.15%
Operating Profit -$3.421M
YoY Change 161.94%
Interest Expense $0.00 -$10.00K $150.0K
YoY Change -100.0% -106.67% 1400.0%
% of Operating Profit
Other Income/Expense, Net -$178.0K $180.0K $250.0K
YoY Change -127.09% -28.0% 31.58%
Pretax Income -$3.243M -$1.960M -$1.010M
YoY Change 399.69% 94.06% 146.34%
Income Tax $9.000K $10.00K -$30.00K
% Of Pretax Income
Net Earnings -$3.252M -$1.960M -$980.0K
YoY Change 400.31% 100.0% 133.33%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$271.7K -$219.2K -$158.1K
COMMON SHARES
Basic Shares Outstanding 11.96M
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q1 2018 Q4 2017 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $13.76M $16.82M $1.350M
YoY Change 104.75% 1145.93% -22.41%
Cash & Equivalents $2.759M $16.82M $1.353M
Short-Term Investments $11.00M
Other Short-Term Assets $300.0K $370.0K $60.00K
YoY Change 500.0% 516.67% -14.29%
Inventory
Prepaid Expenses $369.0K $61.00K
Receivables $929.0K $780.0K $80.00K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $14.94M $17.97M $1.494M
YoY Change 97.41% 1102.95% -19.24%
LONG-TERM ASSETS
Property, Plant & Equipment $90.00K $96.00K $37.00K
YoY Change 28.57% 159.46% 85.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $270.0K $270.0K $270.0K
YoY Change 0.0% 0.0%
Total Long-Term Assets $550.0K $367.0K $308.0K
YoY Change 66.67% 19.16% 1440.0%
TOTAL ASSETS
Total Short-Term Assets $14.94M $17.97M $1.494M
Total Long-Term Assets $550.0K $367.0K $308.0K
Total Assets $15.49M $18.34M $1.802M
YoY Change 96.13% 917.7% -3.64%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $685.0K $483.0K $920.0K
YoY Change 7.03% -47.5% 178.79%
Accrued Expenses $686.0K $808.0K
YoY Change 67.32%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $10.00K $10.00K $0.00
YoY Change
Total Short-Term Liabilities $1.425M $1.296M $1.003M
YoY Change 28.38% 29.21% 59.21%
LONG-TERM LIABILITIES
Long-Term Debt $20.00K $20.00K $0.00
YoY Change
Other Long-Term Liabilities $150.0K
YoY Change -92.72%
Total Long-Term Liabilities $163.0K $18.00K
YoY Change -92.09%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.425M $1.296M $1.003M
Total Long-Term Liabilities $163.0K $18.00K
Total Liabilities $1.588M $1.314M $1.003M
YoY Change -49.91% 31.01% 59.21%
SHAREHOLDERS EQUITY
Retained Earnings -$49.22M -$45.97M -$40.23M
YoY Change 14.25%
Common Stock $0.00 $0.00 $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $13.91M $17.03M $799.0K
YoY Change
Total Liabilities & Shareholders Equity $15.49M $18.34M $1.802M
YoY Change 96.13% 917.7% -3.64%

Cashflow Statement

Concept 2019 Q1 2018 Q4 2017 Q4
OPERATING ACTIVITIES
Net Income -$3.252M -$1.960M -$980.0K
YoY Change 400.31% 100.0% 133.33%
Depreciation, Depletion And Amortization $6.000K $10.00K $0.00
YoY Change 50.0%
Cash From Operating Activities -$3.134M -$1.900M -$970.0K
YoY Change 235.19% 95.88% -25.38%
INVESTING ACTIVITIES
Capital Expenditures $10.00K -$10.00K
YoY Change -200.0% 0.0%
Acquisitions
YoY Change
Other Investing Activities -$10.93M
YoY Change
Cash From Investing Activities -$10.93M $10.00K -$10.00K
YoY Change 34050.0% -200.0% 0.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -2.000K 14.82M 1.550M
YoY Change -100.03% 856.13% 15400.0%
NET CHANGE
Cash From Operating Activities -3.134M -1.900M -970.0K
Cash From Investing Activities -10.93M 10.00K -10.00K
Cash From Financing Activities -2.000K 14.82M 1.550M
Net Change In Cash -14.06M 12.93M 570.0K
YoY Change -362.54% 2168.42% -143.85%
FREE CASH FLOW
Cash From Operating Activities -$3.134M -$1.900M -$970.0K
Capital Expenditures $10.00K -$10.00K
Free Cash Flow -$3.134M -$1.910M -$960.0K
YoY Change 224.1% 98.96% -25.58%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018 dei Amendment Flag
AmendmentFlag
false
CY2018 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2018 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
CY2018 dei Document Period End Date
DocumentPeriodEndDate
2018-12-31
CY2018Q4 dmac Research And Development Incentive Receivable
ResearchAndDevelopmentIncentiveReceivable
622000
CY2018 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2017Q4 dmac Accrued Taxes And Other Liabilities Current
AccruedTaxesAndOtherLiabilitiesCurrent
6000
CY2017 dmac Adjustments To Additional Paid In Capital Warrants Exercised
AdjustmentsToAdditionalPaidInCapitalWarrantsExercised
615000
CY2018 dmac Adjustments To Additional Paid In Capital Warrants Exercised
AdjustmentsToAdditionalPaidInCapitalWarrantsExercised
731000
CY2018 dei Entity Central Index Key
EntityCentralIndexKey
0001401040
CY2018 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2018 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2018 dei Entity Registrant Name
EntityRegistrantName
DiaMedica Therapeutics Inc.
CY2018 dei Trading Symbol
TradingSymbol
dmac
CY2018Q4 dmac Advances To Vendor
AdvancesToVendor
271000
CY2017Q4 dmac Advances To Vendor
AdvancesToVendor
271000
CY2018 dei Document Type
DocumentType
10-K
CY2019Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
11956874
CY2018 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2018 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2018Q2 dei Entity Public Float
EntityPublicFloat
59800000
CY2018 dei Entity Shell Company
EntityShellCompany
false
CY2018 dei Entity Small Business
EntitySmallBusiness
true
CY2018 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2018 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2018Q4 dmac Accrued Clinical Study Costs Current
AccruedClinicalStudyCostsCurrent
292000
CY2017Q4 dmac Accrued Clinical Study Costs Current
AccruedClinicalStudyCostsCurrent
CY2018Q4 dmac Accrued Research And Professional Fees Current
AccruedResearchAndProfessionalFeesCurrent
65000
CY2017Q4 dmac Accrued Research And Professional Fees Current
AccruedResearchAndProfessionalFeesCurrent
45000
CY2018Q4 dmac Accrued Taxes And Other Liabilities Current
AccruedTaxesAndOtherLiabilitiesCurrent
34000
CY2018Q4 dmac Deferred Tax Assets Property Patents And Other
DeferredTaxAssetsPropertyPatentsAndOther
293000
CY2017Q4 dmac Deferred Tax Assets Property Patents And Other
DeferredTaxAssetsPropertyPatentsAndOther
319000
CY2018Q4 dmac Deferred Tax Assets Property Share Issue Costs
DeferredTaxAssetsPropertyShareIssueCosts
529000
CY2017Q4 dmac Deferred Tax Assets Property Share Issue Costs
DeferredTaxAssetsPropertyShareIssueCosts
117000
CY2018 dmac Effective Income Tax Rate Reconciliation Change In Unrecognized Temporary Differences Amount
EffectiveIncomeTaxRateReconciliationChangeInUnrecognizedTemporaryDifferencesAmount
1131000
CY2017 dmac Effective Income Tax Rate Reconciliation Change In Unrecognized Temporary Differences Amount
EffectiveIncomeTaxRateReconciliationChangeInUnrecognizedTemporaryDifferencesAmount
534000
CY2018 dmac Effective Income Tax Rate Reconciliation Income Tax Recovery Amount
EffectiveIncomeTaxRateReconciliationIncomeTaxRecoveryAmount
-1119000
CY2017 dmac Effective Income Tax Rate Reconciliation Income Tax Recovery Amount
EffectiveIncomeTaxRateReconciliationIncomeTaxRecoveryAmount
-1160000
CY2018 dmac Effective Income Tax Rate Reconciliation Revaluation Of Warrant Liability Amount
EffectiveIncomeTaxRateReconciliationRevaluationOfWarrantLiabilityAmount
450000
CY2017 dmac Effective Income Tax Rate Reconciliation Revaluation Of Warrant Liability Amount
EffectiveIncomeTaxRateReconciliationRevaluationOfWarrantLiabilityAmount
2000
CY2018 dmac Income From Governmental Assistance
IncomeFromGovernmentalAssistance
1214000
CY2017 dmac Income From Governmental Assistance
IncomeFromGovernmentalAssistance
244000
CY2017 dmac Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
CY2018 dmac Relcassification Of Warrant Liability Upon Warrant Exercise
RelcassificationOfWarrantLiabilityUponWarrantExercise
123000
CY2017 dmac Relcassification Of Warrant Liability Upon Warrant Exercise
RelcassificationOfWarrantLiabilityUponWarrantExercise
CY2018 dmac Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
5840000
CY2017Q4 dmac Research And Development Incentive Receivable
ResearchAndDevelopmentIncentiveReceivable
CY2017 dmac Research Grant Recognized Research Activities Performed2016
ResearchGrantRecognizedResearchActivitiesPerformed2016
244000
CY2018 dmac Research Grant Recognized Research Activities Performed2017
ResearchGrantRecognizedResearchActivitiesPerformed2017
593000
CY2018 dmac Research Grant Recognized Research Activities Performed2018
ResearchGrantRecognizedResearchActivitiesPerformed2018
621000
CY2018Q4 dmac Rights Exercisable Percent Of Discount To Market Price
RightsExercisablePercentOfDiscountToMarketPrice
0.5
CY2018Q4 dmac Rights Threshold Trigger To Be Exercisable Percent Of Common Stock Outstanding Owned By Individual
RightsThresholdTriggerToBeExercisablePercentOfCommonStockOutstandingOwnedByIndividual
0.2
CY2017 dmac Stock And Warrants Issued During Period Value Common Stock And Warrants
StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants
2917000
CY2018 dmac Stock And Warrants Issued During Period Value Common Stock And Warrants
StockAndWarrantsIssuedDuringPeriodValueCommonStockAndWarrants
5840000
CY2018 dmac Stock Issued During Period Shares Exercise Of Common Stock Warrants
StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants
128594
CY2017 dmac Stock Issued During Period Shares Exercise Of Common Stock Warrants
StockIssuedDuringPeriodSharesExerciseOfCommonStockWarrants
134079
CY2018 dmac Warrants And Rights Exercises In Period
WarrantsAndRightsExercisesInPeriod
123000
CY2018Q4 dmac Working Capital
WorkingCapital
16700000
CY2018Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1291000
CY2017Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
919000
CY2018Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
483000
CY2017Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
513000
CY2018Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
780000
CY2017Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
80000
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
24000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
26000
CY2018Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
62993000
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
41033000
CY2017 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
292000
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
620000
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
409000
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1468105
CY2017 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
717431
CY2018Q4 us-gaap Assets
Assets
18339000
CY2017Q4 us-gaap Assets
Assets
1802000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
17972000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
1494000
CY2018Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
367000
CY2017Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
308000
CY2018Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
1591479
CY2018Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2017Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2018Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
5000
CY2017Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
CY2018Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
18000
CY2017Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
CY2018Q4 us-gaap Cash
Cash
16823000
CY2017Q4 us-gaap Cash
Cash
1353000
CY2016Q4 us-gaap Cash
Cash
1736000
CY2018 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
15470000
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-383000
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2017 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11956874
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6370661
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11956874
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6370661
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
CY2018 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Concentration of credit risk</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash. Cash is deposited in demand and savings accounts at commercial banks. At times, such deposits <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>be in excess of insured limits. The Company has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> experienced any losses on its deposits of cash.</div></div></div></div></div></div></div></div></div></div></div>
CY2018Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
887000
CY2017Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
887000
CY2018Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
CY2017Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
CY2018Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
10886000
CY2017Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
8552000
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
9280000
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
7233000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
10886000
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
8552000
CY2018Q4 us-gaap Deferred Tax Liabilities Deferred Expense
DeferredTaxLiabilitiesDeferredExpense
97000
CY2017Q4 us-gaap Deferred Tax Liabilities Deferred Expense
DeferredTaxLiabilitiesDeferredExpense
CY2018Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
6000
CY2017Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
4000
CY2018 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
45000
CY2017 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
33000
CY2018 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.04
CY2018Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
271000
CY2017Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
271000
CY2018 us-gaap Depreciation
Depreciation
15000
CY2017 us-gaap Depreciation
Depreciation
4000
CY2018Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
CY2017Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
84000
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.72
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.74
CY2018 us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
24000
CY2017 us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.27
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.27
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
417000
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
355000
CY2018 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y3D
CY2017 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y354D
CY2018Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
1400000
CY2017Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
551000
CY2018 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
39000
CY2017 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-9000
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2739000
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1313000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-5654000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-4260000
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
80000
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
CY2018 us-gaap Income Tax Reconciliation Nondeductible Expense Research And Development
IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
103000
CY2017 us-gaap Income Tax Reconciliation Nondeductible Expense Research And Development
IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
314000
CY2018 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
243000
CY2017 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
110000
CY2018 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
172000
CY2017 us-gaap Income Tax Reconciliation Other Reconciling Items
IncomeTaxReconciliationOtherReconcilingItems
204000
CY2018Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
134000
CY2017Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
CY2018 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
372000
CY2017 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
248000
CY2018 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
700000
CY2017 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
27000
CY2018 us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
CY2017 us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
271000
CY2018 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
308000
CY2017 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-6000
CY2018 us-gaap Interest Paid Net
InterestPaidNet
11000
CY2017 us-gaap Interest Paid Net
InterestPaidNet
57000
CY2018Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
244000
CY2018Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
64000
CY2018Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
46000
CY2018Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
68000
CY2018Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
66000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
18339000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1802000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1296000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1003000
CY2018Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
18000
CY2017Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
21216000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3539000
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-50000
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-22000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5696000
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3900000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-5734000
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-4260000
CY2018 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1107000
CY2017 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
259000
CY2018 us-gaap Operating Expenses
OperatingExpenses
7261000
CY2017 us-gaap Operating Expenses
OperatingExpenses
4519000
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-6761000
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-4519000
CY2018 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-68000
CY2017 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
6000
CY2018Q4 us-gaap Other Receivables
OtherReceivables
24000
CY2017Q4 us-gaap Other Receivables
OtherReceivables
80000
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
50000
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
22000
CY2018Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
369000
CY2017Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
61000
CY2018 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
14726000
CY2017 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2917000
CY2018 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
43000
CY2017 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
7000
CY2018 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
607000
CY2017 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
615000
CY2018 us-gaap Property Plant And Equipment Disposals
PropertyPlantAndEquipmentDisposals
17000
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
120000
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
63000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
96000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
37000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-45968000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-40234000
CY2018 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
500000
CY2017 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4522000
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3206000
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
508000
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
213000
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
150739
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
4.48
CY2017Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
3.69
CY2018Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
7.45
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
620000
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
409000
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.011
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
104000
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
12000
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
196800
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
9.30
CY2018Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
397027
CY2018Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
639359
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P4Y182D
CY2017Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
216793
CY2018Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
242332
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
20522
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
7.27
CY2018 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
P7Y36D
CY2018Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
7.87
CY2018 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P7Y292D
CY2017 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
409000
CY2018 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
620000
CY2018 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
16954
CY2017 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
3000
CY2018 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
14726000
CY2017 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
7000
CY2018 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
43000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
17025000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
1111000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
799000
CY2018 us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Use of estimates</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Actual results could differ from those estimates.</div></div></div></div></div></div></div></div></div></div></div>
CY2017Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
84000
CY2018Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
7743520
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
5935790

Files In Submission

Name View Source Status
0001437749-19-005272-index-headers.html Edgar Link pending
0001437749-19-005272-index.html Edgar Link pending
0001437749-19-005272.txt Edgar Link pending
0001437749-19-005272-xbrl.zip Edgar Link pending
chart01.jpg Edgar Link pending
chart02.jpg Edgar Link pending
chart03.jpg Edgar Link pending
chart04.jpg Edgar Link pending
chart05.jpg Edgar Link pending
chart06.jpg Edgar Link pending
chart07.jpg Edgar Link pending
dmac-20181231.xml Edgar Link completed
dmac-20181231.xsd Edgar Link pending
dmac-20181231_cal.xml Edgar Link unprocessable
dmac-20181231_def.xml Edgar Link unprocessable
dmac-20181231_lab.xml Edgar Link unprocessable
dmac-20181231_pre.xml Edgar Link unprocessable
dmtp20181231_10k.htm Edgar Link pending
ex_137868.htm Edgar Link pending
ex_137869.htm Edgar Link pending
ex_137957.htm Edgar Link pending
ex_137958.htm Edgar Link pending
ex_137959.htm Edgar Link pending
ex_137960.htm Edgar Link pending
ex_137961.htm Edgar Link pending
ex_137962.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
graph01.jpg Edgar Link pending
image01.jpg Edgar Link pending
image02.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending